Additional file 4 of Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
figure
posted on 2022-01-05, 04:43 authored by Osman Öcal, Regina Schinner, Kerstin Schütte, Enrico N. de Toni, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Antonio Gasbarrini, Bruno Sangro, Maciej Pech, Peter Malfertheiner, Jens Ricke, Max SeidenstickerAdditional file 4: Supplementary Fig. 4. Progression-free survival of patients with ETS ≥ 20% vs. ETS < 20%. CI, confidence interval; ETS, early tumor shrinkage; HR, hazard ratio; PFS, progression-free survival.
